Sanofi SA

0A2V

Company Profile

  • Business description

    Sanofi develops and markets drugs with a concentration in vaccines, immunology, oncology, cardiovascular disease, diabetes, and over-the-counter treatments. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing about 30% of total sales, but profits are shared with Regeneron. Just over 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.

  • Contact

    46, Avenue de la Great Army
    Paris75017
    FRA

    T: +33 153774000

    E: [email protected]

    https://www.sanofi.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - General

    Fiscal Year End

    31 December 2025

    Employees

    82,878

Stocks News & Analysis

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,133.106.200.08%
CAC 407,807.0069.36-0.88%
DAX 4022,186.10353.88-1.57%
Dow JONES (US)41,989.9611.80-0.03%
FTSE 1008,577.2257.58-0.67%
HKSE23,202.534.31-0.02%
NASDAQ17,449.89150.600.87%
Nikkei 22535,725.87101.390.28%
NZX 50 Index12,320.197.590.06%
S&P 5005,633.070.000.00%
S&P/ASX 2007,934.509.300.12%
SSE Composite Index3,350.131.690.05%

Market Movers